with I Chief business Along our us Michael review ENDRA’s Renaud Officer; Officer David to update. today third Technology are ENDRA’s and Kim. you, joining today’s Chief performance Thank afternoon, Commercial and Good and XXXX for Thank as CFO. Wells, Maloberti, me Thornton, call XXXX you everyone. quarter mentioned, on David
agenda. me Let through today's go
with review regulatory we'll last it David in major Q&A. over where first milestones call highlight activities Renaud open details an I'll achievements to our approval Then before initial focus handing and Europe First we our the financials. provide on for commercial the have will week on to achieved recent the including finally,
but is to new allows the to who acoustic platform those also of may thermo ultrasound For the disruptive similar at scans lower of be It enhanced quickly ultrasound in pioneer at TAEUS point as we're that is patient TAEUS complete ENDRA you minutes ways of a TAEUS. works technology story, in within tissue it as use XX systems, visualize MRI, clinicians an can the known with widespread to care. cost. are simple which global use. times existing to
is a major have TAEUS GE healthcare, supports plans, We manufacturers ultrasound. which with compatible our all collaboration commercialization of with but
disease NASH or TAEUS diagnostic NASH. and year. I our liver an liver As we've by continue there fat primary like assess and to for called our focus encouraged affected than progress NAFLD, steatohepatitis the billion by this tool one nonalcoholic before, Accordingly shared to initial and monitor is help is practical to globally very more also nonalcoholic acute need market be NAFLD people
of global this As us of CE that we begin mark. liver light The of a with the approval European reminder in countries giving green imaging COVID-XX efforts this in timing regulatory commercialization system recognize received fatty to year, our for mark probe pandemic. the outbreak TAEUS first CE quarter the the coincided approval
forward the moment. we In The pandemic the in years However, of the let of unprecedented global spite slowdowns. of plan our mark CE progress to safety get in collection we remain of We'll global Renaud updates in timing that problem and a continue the to by and investors schedule roughly fact the notification the capitalize encouraged the provide FDA submission we they control premarket to while Europe on quarter. customary with review with continue the execute into going materialize. submission remain process Drug collaborative paid of culmination engaging system finalize Food the despite XXX-K during the relevant our XXXX cycle, submitted second I'll Administration. to on process to performance and us. of in time the the tirelessly FDA business has June details the At of represented we been this issues, research, implementation, approval regarding worked the and -- quality team can't ENDRA scientific the US and as our data we this year,
executing ENDRA team plan, three review elements. FDA's centers the on which our During components key process, global the the is commercialization actively key of
clinical three the teams. build -- Europe. First, commercial and evaluation local in and three three sites sites excuse global currently global sites, in establish clinical sites US four of reference the me; cultivate evidence ENDRA's countries in market target base We for have one
other regions. work Second TAEUS to in in in drive each clinical element market salespeople GE ENDRA support in clearance person US we will pursue These and is clinical Europe sales evaluation and and our one the to development opportunities receive commercial plan a target sites, commercial build FDA team, teams also after hybrid, segments. sales with of in key independently then hepatology country small radiology
the plan necessitated third highlight mind, now our element education e-marketing first happy commercial more COVID online plan much TAEUS' in quarter and to With finalized our The a we of clinical I'm and presence this to features world. global our report build out second in before contingent when We'll tools, to is benefits legal that advanced the review, sights final clinical the during as in to we in two COVID. European of months coming operational and announce end European European they operations formally business evaluation execute start scanning more expect have these patients the sites the on with site for remaining which Germany year.
Wisconsin to expect yearend. be agreements the and US clinical deemed its far at process, It's were clinical of clearance. US. currently is conducted installed US institutions for first of evaluation the low Review evaluation system TAEUS our research regulatory we clinical in under two Board clinical College active, to and scanned the study. the The study place from week permitting, data NASH Center required Ivins The not world before clearance. Rocky US be Medical has our include use by that can before a Pittsburgh that worth These be Vista's which other TAEUS receiving to our sites sites data technology will with signed reemphasizing the location As real being cases first collecting COVID NAFLD, University are evaluation commercial that three FDA now in last Utah in allows ahead University FDA be of XXX-K to Medical are by risk Vista we'll for With US game evaluation Vista the that announced support launch. clearance Institutional Rocky the we Rocky and concerned, sites are as
clearance, evaluation our reference as look US these to Following can great we forward teams. XXX-K commercial commercial sites sites for
strong. to on agreement Moving GE our Healthcare, the partnership with collaboration remains
calls regular to efforts strategic market opportunity remain we ramp as and over resources renewal it has have and introducing for up confident and will plans, continues coordinate the in to share is XXXX COVID-XX be as diagnostics feedback. conditions Europe customers commercial continue and renewed there years. we four to permit. as GE us January allocate agreement market to This view is up We it last a key commercial in as liver been
applications. portfolio property future we've also our strong technology progress defend intellectual made quarter, the current our to building in During and
worth XX applications beyond issued, applications. XX of assets of applications grants patent patent stands assets the XXXX. IP the It's that expand liver and pending continue portfolio our and highlighting end filed, for defined up currently the at applications, recent to potential, as NASH Our TAEUS several at from clinical and licensed the that's NAFLD,
an visualize tools on patent the diagnostic cancer addressable patent XX markets. protection newest of disease bolster to other European to clinical portfolio point-of-care applications our the additional IP beyond full technology For and provides billion well microvascular This opportunity provide liver for remain the tissues represents committed ENDRA's by expansion market damaged this to trauma. in and market example, growing compelling flows and fluid space. current The in core as agent opportunities time as staff protection or
use of an NASH treat development therapies compounds market the companies There seeing in leading to contract development forecast the Drug billion the organizations in $XX NASH. are pharmaceutical Speaking coming around and ENDRA to opportunities, expansion from research uptick over and NAFLD, same a of XX for clinical end-user grow in and NAFLD pharmaceutical potentially savings clinicians to in years. is of in we're liver companies represent ENDRA's that simpler, way noninvasive and the as deliver such to their liver and studies face measurements technology and cost-effective biopsy faster fat. measurement do. challenges as companies clinical cost studies development to MRI time biomarkers
lies three in technology Specifically, proposition areas. of value pharmaceutical for the companies ENDRA's
trial and have historically to rejection patient liver or rates exceed XX%. speed depends biopsy clinical help recruitment, MRI on currently that First, recruitment which
want fat during to during can of liver fat between a provide and and up pharmaceutical study companies easier, study. measures sooner. to the trends biopsy quickly change Liver Second, interim pick measures MRI
including that that While a treatment. have of target NAFLD, technology such between drugs and the other liver companies pharmaceutical in fat, monitor approved in their in NASH after the drugs natural also things biomarkers interest are an development third pathways a a perspective, fat measurement a interest pharmaceutical directly approved inflammation the direct many have suitable learning understanding companies the point-of-care multitude are patients liver if pharma targeting as ENDRA's for therapy cost-effective; then the from of tools metabolic synergy as to and we're identify
compelling opportunities. the offers other ENDRA's three from the On perspective, side pharmaceutical sector
of with data at pharma First, have Canada. to evidence clinical ongoing that potentially support of in could embedding the valuable our the artificial research in The ENDRA clinical sector also intelligence our the TAEUS trials technology could market. University accelerates in from data volume clinical Western feed bolus provide we clinical commercialization
a our clinical ENDRA deployment and across commercial hundreds pharmaceutical of substantial for be studies. there for enrolled to sell their opportunity companies in sites CROs the Second, the could to technology
equipment are technology to approved, of that would and for market the and when gastroenterologists. companies and with pharmaceutical the To these would interest beyond prescribing to physicians. side. GE they our occur complement the can ultrasound initial after contrary, with the expand note NAFLD, of the partnership leverage NAFLD, pharmaceutical dramatically partnerships on commercial the pharmaceutical Important finally, not NASH and the Third market end-user if companies NASH ENDRA's deals opportunity envision and with drugs TAEUS clinical conflict front on radiologists relationships we lines
the system ending IP here. we've to I'd challenging to our our times expanding David? company and September portfolio. results for keep stay Bottom Wells the first Rocky to I made deploying Europe the Vista, our third in progress XX, review turn am the pleased the during track, on the now So to advancing financial with over tuned like line at call activities commercialization XXXX. David quarter very
